| Company Name: |
ChemShuttle, Inc. |
| Tel: |
0510-83588313-811 18800520310 |
| Email: |
sales@chemshuttle.com |
FX-909 manufacturers
- FX-909
-
- $1520.00
-
2026-05-11
- CAS:2924573-90-8
- Purity: 99.53%
- Supply Ability: 10g
|
| Product Name: | FX-909 | | Synonyms: | FX-909;3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile;FX-909(FTX-6746);Benzonitrile, 3-(5,7-difluoro-1,4-dihydro-4-oxo-2-quinolinyl)-4-(methylsulfonyl)- | | CAS: | 2924573-90-8 | | MF: | C17H10F2N2O3S | | MW: | 360.34 | | EINECS: | | | Product Categories: | | | Mol File: | 2924573-90-8.mol |  |
| | FX-909 Chemical Properties |
| Boiling point | 584.3±50.0 °C(predicted) | | density | 1.55±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | solubility | Acetonitrile: Slightly soluble: 0.1-1 mg/ml
DMSO: Sparingly soluble: 1-10 mg/ml
Water: Slightly soluble: 0.1-1 mg/ml | | pka | -0.69±0.70(predicted) | | form | Solid | | color | White to off-white |
| | FX-909 Usage And Synthesis |
| Uses | FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist. FX-909 can be used for the research of cancer[1]. | | in vivo | FX-909 (0.03-1 mg/kg; BID for 21 days) shows anticancer effects in UMUC9 UC xenograft mouse model[1]. | | IC 50 | PPARγ | | References | [1] Mertz J A, et al. Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG). Cancer Research, 2023, 83(7_Supplement): 2802-2802.
[2] SIMS R, MERTZ J A, WILSON J E, et al. Abstract ND08: Discovery of FX-909, a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor, to potentially treat patients with the luminal subtype of advanced urothelial cancer (UC)[J]. Cancer research, 2023, 8 1: 0. DOI: 10.1158/1538-7445.am2023-nd08 |
| | FX-909 Preparation Products And Raw materials |
|